Ro 23-9424 is a novel ester-linked codrug of fleroxacin (Ro 23-6240; AM-833) and the cefotaxime metabolite desacetylcefotaxime. Its potency was determined against over 1,000 organisms and found to be intermediate between those of the two components. More than 99% of members of the family Enterobacteriaceae were inhibited by .8 ,ug of Ro 23-9424 per ml; its MIC for 50% of strains tested ranged from <0.06 to 1 ,ug/ml. Staphylococci, streptococci, Branhamella catarrhalis, Corynebacterium jeikeium, Bacillus spp., Haemophilus influenzae, Listeria monocytogenes, and the pathogenic Neisseria spp., including oxacillin-resistant Staphylococcus aureus, P-lactamase-producing strains, and penicillin-resistant pneumococci, were also inhibited by Ro (4, 5, (10) (11) (12) . In fact, as the antimicrobially active metabolite of cefotaxime (13), desacetylcefotaxime enhances cefotaxime activity against aerobic (5, 12) and anaerobic (10, 11) bacteria. Cefotaxime is converted to desacetylcefotaxime via the same esterase mechanism as the separation of the components of Ro 23-9424. Fleroxacin has * Corresponding author. a spectrum of activity comparable to those of other fluoroquinolones, such as norfloxacin and ofloxacin, but is slightly less active than ciprofloxacin, especially against gram-positive cocci (4, 10). These component antimicrobial agents produce a dual mode of action that is not unlike that of the compound reported by O'Callaghan et al. in 1976 (23). That cephalosporin-omadine combination was quite effective in vitro but failed as a therapeutic agent because of omadinerelated toxicity (6, 23). Ten years later, Mobashery et al. (15, 17) described a cephalosporin-dipeptide ester that possessed in vitro activity against many strains of gram-positive and gram-negative species. Both of these cephem ester codrugs only produced an active second compound (noncephalosporin) after the cephalosporin beta-lactam ring was hydrolyzed by P-lactamases (3, (15) (16) (17) 23 441, 1988).
press). The fused drug is moderately stable to esterases after intravenous administration, having pharmacokinetics most similar to that of the cephalosporin component (J. G. Christenson, K. K. Chan, H. H. Farrish, I. H. Patel, and A. Specian, Program Abstr. 28th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 449, 1988 ). However, a consistently low level (1 ,ug/ml) of fleroxacin was found in various animal sera. This drug, therefore, differs from several clinically used esterified cephalosporins (8) or betalactams (14, 26) that are more rapidly modified by tissue or circulating esterases to their most active forms. In general, when two compounds linked by ester bonds, e.g., ampicillin and probenecid, ampicillin and mecillinam, or ampicillin and sulbactam, are administered, and in vivo concentrations of each component are equal without significant persistence of the esterified form (1, 2, 7, 9, 14, 26 ; B. G. Christensen and W. J. Leanza, U.S. patent 3,931,150, January 1976). Ro 23-9424 is excreted primarily intact by the kidneys and has a half-life of 75 min in primates.
The individual comnponents of Ro 23-9424 are each very active against a number of gram-positive and gram-negative pathogens (4, 5, (10) (11) (12) . In fact, as the antimicrobially active metabolite of cefotaxime (13) , desacetylcefotaxime enhances cefotaxime activity against aerobic (5, 12) and anaerobic (10, 11) bacteria. Cefotaxime is converted to desacetylcefotaxime via the same esterase mechanism as the separation of the components of Ro 23-9424. Fleroxacin has * Corresponding author. a spectrum of activity comparable to those of other fluoroquinolones, such as norfloxacin and ofloxacin, but is slightly less active than ciprofloxacin, especially against gram-positive cocci (4, 10) . These component antimicrobial agents produce a dual mode of action that is not unlike that of the compound reported by O'Callaghan et al. in 1976 (23) . That cephalosporin-omadine combination was quite effective in vitro but failed as a therapeutic agent because of omadinerelated toxicity (6, 23) . Ten years later, Mobashery et al. (15, 17) described a cephalosporin-dipeptide ester that possessed in vitro activity against many strains of gram-positive and gram-negative species. Both of these cephem ester codrugs only produced an active second compound (noncephalosporin) after the cephalosporin beta-lactam ring was hydrolyzed by P-lactamases (3, (15) (16) (17) 23 Bacteroides fragilis group strains, and 40 other nonenteric gram-negative bacilli (Tables 1 and 3) .
In addition, we tested 60 isolates that were resistant or only moderately susceptible to ciprofloxacin (MIC, >1 ,ug/ ml) or norfloxacin (MIC >4 ,ug/ml). Strains Table 3 ). Group JK Corynebacterium strains were significantly inhibited by fleroxacin (M'C50, 1 pLg/ml) and Ro 23-9424 (MlC50, 2 ,ug/ml) but not by cefotaxime or desacetylcefotaxime. Activity against infrequently isolated species. The Ro 23-9424 MICs for 99 additional organisms are given in Table 3 . Ro 23-9424 was very active against the 38 enteric bacilli representing nine species (MIC1OO, 1 ,ugIml). MICs were -32 [Lg/ml for only Achromobacter xylosoxidans (two strains) and Pseudomonas fluorescens (one strain).
Activity against all aerobic organisms. The five antimicrobial agents listed in Tables 1 and 2 plus aztreonam, cefoperazone, ceftazidime, ciprofloxacin, and imipenem were tested against all the aerobic species we used (945 strains). Ro 23-9424 had a spectrum of inhibition (s8 pg/ml) identical to that of the broadest-spectrum agents, ciprofloxacin (97%) and imipenem (97%). For the 647 gram-negative strains, aztreonam was the least effective, with 11% of strains resistant, compared with resistance rates of 2, 3, and 5% for Ro 23-9424 (MICs, -32 ,ug/ml), ceftazidime (MICs, -32 ,ug/ ml), and cefotaxime (MICs, .64 pLg/ml), respectively. Ceftazidime was the least active agent against the grampositive strains, exhibiting 27% resistance compared with only 7% for cefoperazone. The rank order of spectrum of activity against all organisms was (percentage of resistant strains in parentheses) as follows: ceftazidime (10.4%) < cefotaxime (9.5%) < cefoperazone (8.5%) < Ro 23-9424 (3.3%) < ciprofloxacin (3.2%) < imipenem (2.8%).
Activity against drug-resistant strains. Sixty organisms with more limited susceptibility to ciprofloxacin and norfloxacin (Table 4 , footnote b) were tested against Ro 23-9424 and its hydrolysis components. Of these strains, 45 and 48% were susceptible to desacetylcefotaxime and fleroxacin, respectively. However, Ro 23-9424 inhibited 65 and 85% of the strains <8 and s16 ,ug/ml, respectively.
A total of 19 ceftazidime-resistant (MIC, >16 [Lg/ml) gram-negative bacilli were identified in the test organism collection. Ro 23-9424 inhibited 95% of these organisms at 16 p.g/ml, compared with 68% for fleroxacin (.2 ,ug/ml) and 5% for desacetylcefotaxime (.8 ,ug/ml; data not shown).
Bactericidal activity and inoculum effects. and were also consistent with the reported twofold-higher enzyme stability of desacetylcefotaxime than cefotaxime (25) . The fused compound also appeared to be bactericidal against the Enterococcus faecalis strain (MIC and MBC, 16 [Lg/ml).
Preliminary disk diffusion tests. NCCLS-recommended quality control strains were processed concurrently with these studies, and investigator-prepared 10- If the cefotaxime-like pharmacokinetics are substantiated in humans, along with associated low, nontoxic fleroxacin levels, an Ro 23-9424 susceptibility breakpoint MIC of c8 or .16 p.g/ml would be possible and consistent with results for other cephalosporins (22) . At these breakpoint concentrations, the Ro 23-9424 spectrum includes virtually all clinically relevant gram-positive and gram-negative aerobes, including strains resistant to quinolones or newer cephalosporins (Table 3 ). This degree of activity was most comparable to that of ciprofloxacin and imipenem. In vivo activity has been proven by animal model experiments with fluoroquinolone-resistant and cefotaxime-resistant organisms (Beskid et al., submitted). Ro This fusion product of two potent compounds seems quite different from other clinically utilized ester-linked drugs (1, 2, 7, 16) or uses of an ester to improve the gastrointestinal absorption of a drug (8, 10, 14) . Unlike previously reported co-or prodrugs, Ro 23-9424 seems best applied by parenteral routes, and its activity does not rely entirely on active free components (1, 2, 7, 14; Christensen and Leanza, patent) or their potentially favorable interaction (1, 7, 9) . The greater esterase stability of the Ro 23-9424 structure could allow higher, possibly nontoxic quinolone concentrations in the bacterial periplasmic space following Ro 23-9424-penicillinbinding protein interactions (Georgopapadakou et al., in press). Mutual prodrugs such as sultamicillin have been successful as orally administered antimicrobial agent combinations (1) . If similar findings are confirmed in Ro 23-9424 human trials, this fused codrug will be a valuable addition to the chemotherapy of infections caused by either cephalosporin-or fluoroquinolone-resistant pathogens.
